Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001225613 | SCV001397897 | pathogenic | Tuberous sclerosis 2 | 2020-12-01 | criteria provided, single submitter | clinical testing | Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in TSC2 are known to be pathogenic (PMID: 10205261, 17304050). This sequence change affects a donor splice site in intron 29 of the TSC2 gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is not present in population databases (ExAC no frequency). Disruption of this splice site has been observed in individuals affected with clinical features of tuberous sclerosis complex (PMID: 27406250, 10533067, Invitae). ClinVar contains an entry for this variant (Variation ID: 49256). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV002490589 | SCV002791566 | pathogenic | Lymphangiomyomatosis; Isolated focal cortical dysplasia type II; Tuberous sclerosis 2 | 2021-12-16 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001225613 | SCV003823713 | pathogenic | Tuberous sclerosis 2 | 2022-04-29 | criteria provided, single submitter | clinical testing | |
Tuberous sclerosis database |
RCV000042515 | SCV000066306 | not provided | Tuberous sclerosis syndrome | no assertion provided | curation |